Cardinal Health Inc (CAH) Q2 2025 Earnings Call Highlights: Strong Pharma Growth Amid Revenue ...
Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment performance and strategic acquisitions.
Cardinal Health, Inc. (NYSE:CAH) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript January 30, 2025 Cardinal Health, Inc. beats earnings expectations. Reported EPS is $1.93, expectations were $1.74. Operator: Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc.
Cardinal Health reports Q2 results, raises fiscal year 2025 outlook
Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.
Cardinal Health, Inc. (CAH) Q2 2025 Earnings Call Transcript
Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is being recorded.
Cardinal Health Inc Q2 Profit Increases, Beats Estimates
Cardinal Health Inc (CAH) revealed a profit for its second quarter that increased from last year and beat the Street estimates. The
Cardinal: Fiscal Q2 Earnings Snapshot
The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $1.75 per share. The prescription drug distributor posted revenue of $55.26 billion in the period, also topping Street forecasts.
Cardinal Health (CAH) Surpasses Q2 Earnings and Revenue Estimates
Cardinal Health (CAH) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.82 per share a year ago. These figures are adjusted for non-recurring items.
Cardinal Health raises FY25 EPS guidance to $7.85-$8 amid specialty growth and acquisitions
Q2 2025 Management View CEO Jason Hollar emphasized strong Q2 performance driven by robust demand in Pharmaceutical and ...
Cardinal Health’s Strong Performance and Strategic Acquisitions Justify Buy Rating
Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday.Invest with ...
Modern Healthcare20h
Cardinal Health CEO Jason Hollar issues warning on tariffs
Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...
Cardinal Health lifts 2025 profit forecast on specialty drugs demand
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.
Cardinal Health (NYSE:CAH) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says
Cardinal Health (NYSE:CAH – Get Free Report) had its target price hoisted by equities researchers at Wells Fargo & Company from $127.00 to $135.00 in a research note issued on Wednesday,Benzinga ...
Hoodline20h
Dublin City Schools Abandons Cardinal Health Building Purchase, Opts for Scioto High School Expansion
Dublin City Schools has officially backed out of a deal to acquire the vacant Cardinal Health office building, pivoting ...
Cardinal Health price target raised to $156 from $138 at Leerink
Leerink raised the firm’s price target on Cardinal Health (CAH) to $156 from $138 and keeps an Outperform rating on the shares. Q2 results ...
MDM20h
Cardinal Health 2Q Sales Rise 16% Outside of Optimum Impact
Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.